1. Home
  2. MREO vs UMAC Comparison

MREO vs UMAC Comparison

Compare MREO & UMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • UMAC
  • Stock Information
  • Founded
  • MREO 2015
  • UMAC 2019
  • Country
  • MREO United Kingdom
  • UMAC United States
  • Employees
  • MREO N/A
  • UMAC N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • UMAC
  • Sector
  • MREO Health Care
  • UMAC
  • Exchange
  • MREO Nasdaq
  • UMAC Nasdaq
  • Market Cap
  • MREO 311.8M
  • UMAC 267.7M
  • IPO Year
  • MREO N/A
  • UMAC 2024
  • Fundamental
  • Price
  • MREO $1.84
  • UMAC $10.72
  • Analyst Decision
  • MREO Strong Buy
  • UMAC Strong Buy
  • Analyst Count
  • MREO 5
  • UMAC 3
  • Target Price
  • MREO $7.40
  • UMAC $19.33
  • AVG Volume (30 Days)
  • MREO 1.6M
  • UMAC 4.6M
  • Earning Date
  • MREO 11-10-2025
  • UMAC 11-06-2025
  • Dividend Yield
  • MREO N/A
  • UMAC N/A
  • EPS Growth
  • MREO N/A
  • UMAC N/A
  • EPS
  • MREO N/A
  • UMAC N/A
  • Revenue
  • MREO $500,000.00
  • UMAC $8,304,873.00
  • Revenue This Year
  • MREO N/A
  • UMAC $86.94
  • Revenue Next Year
  • MREO $72.16
  • UMAC $118.95
  • P/E Ratio
  • MREO N/A
  • UMAC N/A
  • Revenue Growth
  • MREO N/A
  • UMAC 133.20
  • 52 Week Low
  • MREO $1.47
  • UMAC $2.34
  • 52 Week High
  • MREO $4.29
  • UMAC $23.62
  • Technical
  • Relative Strength Index (RSI)
  • MREO 45.03
  • UMAC 40.23
  • Support Level
  • MREO $1.65
  • UMAC $9.43
  • Resistance Level
  • MREO $1.93
  • UMAC $11.54
  • Average True Range (ATR)
  • MREO 0.12
  • UMAC 1.47
  • MACD
  • MREO -0.02
  • UMAC -0.38
  • Stochastic Oscillator
  • MREO 36.00
  • UMAC 18.56

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About UMAC Unusual Machines Inc. Common Stock

Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.

Share on Social Networks: